CREDIT ANALYSIS: GLYCONICS LIMITED

1. Credit Opinion: DECLINE

Reasoning: Glyconics Limited is a pre-revenue life sciences company that is fundamentally unable to service debt obligations from operational cash flows. The business is loss-making, cash-burning, and entirely dependent on continued equity injections to fund ongoing development activities. Traditional credit facilities are inappropriate for this business profile. The capitalised development costs of £3.28M (which are not being amortised) represent speculative assets with uncertain realisable value, and the company has no trading income to support debt servicing. Any lending would effectively be funding R&D expenditure with repayment contingent on future equity raises or successful commercialisation — neither of which can be guaranteed.

2. Financial Strength

Balance Sheet Summary (Sep 2024): - Net Assets: £3.87M (up from £3.41M in Mar 2024) - Shareholders' Funds: £5.16M (share premium) offset by retained losses of £989K - Share capital: £400

Key Concerns:

Intangible Asset Concentration: Development costs of £3.28M represent 78% of total assets. These are not being amortised as the directors state the asset "is yet to deliver commercial values as they are still in the build phase." This accounting treatment is permissible but masks the true financial position — these costs have no proven commercial value and may require significant impairment if commercialisation fails.

Accumulated Losses: Retained losses of £989K demonstrate persistent operational losses with no revenue generation. The loss trajectory is worsening, not improving.

Equity-Dependent Capital Structure: The balance sheet strength is entirely attributable to £5.16M in share premium — equity invested by shareholders. Without this, the company would be insolvent. This creates key-person/controlling shareholder dependency (Xxxxxx Xxxxxxxxname shown to subscribers holds 50-75% control).

Current Liability Spike: Current liabilities jumped from £70K (Mar 2024) to £320K (Sep 2024) — a 359% increase in six months, suggesting accelerating cash burn and potential creditor pressure.

3. Cash Flow Assessment

Liquidity Position: - Cash: £199,643 (down from £216,453 in Mar 2024, and significantly down from £848,307 in Mar 2022) - Current Assets: £881,523 - Current Liabilities: £320,169 - Net Current Assets: £561,354

Cash Burn Trajectory: | Period | Cash | Net Current Assets | |--------|------|-------------------| | Mar 2022 | £848,307 | £1,561,741 | | Mar 2023 | £498,265 | £1,024,932 | | Mar 2024 | £216,453 | £765,310 | | Sep 2024 | £199,643 | £561,354 |

Cash has declined 76% over two and a half years. Net current assets have fallen 64% in the same period. At the current burn rate, the company faces material liquidity constraints without additional equity funding.

Positive Signals: Debtors include £380K in tax/VAT receivables (likely R&D tax credits), which should convert to cash in the near term, providing temporary relief.

Working Capital Concerns: Stock of £225K appears static between periods, suggesting slow-moving or obsolete inventory. With only 5 employees and no revenue, this stock level is notable.

Going Concern Risk: The directors' going concern assessment relies on "access to adequate resources" — this is implicitly dependent on future equity raises, not operational cash generation. This represents a significant uncertainty.

4. Monitoring Points

If any facility were considered (venture debt/asset-backed), the following metrics require close monitoring:

1. Cash Runway: Monthly cash burn rate and months of runway remaining — currently estimated at 3-6 months without additional funding or tax credit receipts

2. Equity Funding Pipeline: Status and timing of next funding round; any indication of shareholder reluctance to continue funding

3. Commercialisation Milestones: Progress toward regulatory approval, clinical trials, or product launch — critical for validating the £3.28M capitalised development costs

4. R&D Tax Credit Receipts: Confirmation of timing for the £380K receivable — this is the near-term liquidity lifeline

5. Creditor Days: Monitor trade creditor pressure as current liabilities escalate

6. Related Party Transactions: The £36.6K owed by group undertakings and any intercompany funding arrangements require transparency

7. Director Changes: Any departure of key scientific/technical directors could signal business difficulties

8. Filing Compliance: Company changed year-end from March to September — ensure continued timely filing

Additional Observations

Corporate Structure: Multiple directors with PhD qualifications (Xxxxxx Xxxxxxxxname shown to subscribers, Xxxxxx Xxxxxxxxname shown to subscribers, Xxxxxx Xxxxxxxxname shown to subscribers, Xxxxxx Xxxxxxxxname shown to subscribers) indicates a research-heavy organisation typical of early-stage medtech. However, this also suggests high salary commitments without corresponding revenue.

Share Capital: Minimal called-up share capital (£400) with substantial share premium indicates the company has raised funds through share issuances at significant premiums — standard for equity-funded startups but creates expectation of future returns.

No Audit: The company claims audit exemption under the small companies regime. For a business with £4.2M in total assets, the lack of independent audit verification on development cost capitalisation and going concern assumptions is a credit concern.

Names of the people mentioned are shown to subscribers. See subscription